This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Altria Group has been evolving with the changing industry dynamics. Given the rising health consciousness and stern government regulations to discourage smoking, this tobacco behemoth has been moving beyond traditional cigarettes and expanding in the smokeless category. We note that revenues from the oral product category have been steadily rising on the back of growing popularity for reduced risk products. In this respect, Altria is gaining from the sale of IQOS in United States, through its licensing deal with Phillip Morris. Further, Altria’s investment in Cronos Group highlights its focus on exploring the cannabis market.
IMBBY vs. MO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
IMBBY vs. MO: Which Stock Is the Better Value Option?
Altria (MO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Altria (MO) closed the most recent trading day at $55.98, moving +1.1% from the previous trading session.
Altria Focuses on RRPs Growth, Closes Investment in Cronos
by Zacks Equity Research
Altria (MO) closes investment deal in Cronos Group. The move is in sync with the company's efforts to expand in the smokeless category.
Cronos (CRON) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline progress when Cronos (CRON) reports fourth-quarter results.
What Investors Need to Know About Investing in Marijuana Stocks
by Benjamin Rains
Let's look at what investors need to know about the marijuana industry and how to invest in the future of pot.
4 Reasons Why Marijuana Stocks & ETFs Could Be on a High in 2019
by Sanghamitra Saha
Marijuana stocks and related ETFs caught investors' attention last year, courtesy of its mysterious rally in mid-2018 on Canada's legalization of recreational marijuana in October. Let's take a look at whether the space will be able to maintain its rally in 2019.
The Zacks Analyst Blog Highlights: Caterpillar, Netflix, Philip Morris International, Altria and Verizon
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Caterpillar, Netflix, Philip Morris International, Altria and Verizon
Why Marijuana ETFs are on a High in 2019
by Sweta Killa
After being beaten down in the final quarter of 2018, pot stocks staged a nice comeback at the start of this year on the renewed appeal for riskier assets. Here's why ETFs are riding high this year.
Top Analyst Reports for Caterpillar, Netflix & Philip Morris
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Caterpillar (CAT), Netflix (NFLX) and Philip Morris International (PM).
4 Best Marijuana Stocks to Play the Green Rush
by Zacks Equity Research
Whether its eating a gooey, chocolatey brownie or taking a few hits off a freshly rolled joint, it???s common knowledge that a lot of people like to get high. Many investors, however, have yet to "light up." What are the best marijuana stocks out there right now?
Marijuana ETF Joins Billion Dollar Club
by Sweta Killa
Marijuana ETF has now accumulated billion dollars in AUM since its inception in less than 14 months.
Where to Find the Best Marijuana Stocks
by Tracey Ryniec
As the marijuana industry gets more complex, check out the Zacks Market Edge Podcast where host Tracey Ryniec
Top Analyst Reports for Procter & Gamble, Becton, Dickinson & Dominion Energy
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Becton, Dickinson (BDX) and Dominion Energy (D).
The Zacks Analyst Blog Highlights: Cronos, Altria, Canopy and Tilray
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cronos, Altria, Canopy and Tilray
Here's Why Cannabis Stocks (ACB, CRON) Are Gaining Today
by Ryan McQueeney
Shares of several notable cannabis stocks, including Aurora Cannabis (ACB) and Cronos Group (CRON), were up more than 10% through early afternoon trading hours Monday.
5 Top Performing Stocks of Marijuana ETF
by Sweta Killa
We have highlighted five best-performing stocks of the top ETF of January.
Philip Morris (PM) Q4 Earnings: Low Cigarette Volumes to Hurt
by Zacks Equity Research
Philip Morris' (PM) performance in Q4 to be weighed down by declining cigarette sales volumes. However, strength in RRPs and pricing to offer some respite.
Altria (MO) Q4 Earnings Beat, Strong Pricing Aids Revenues
by Zacks Equity Research
Altria's (MO) Q4 performance gains on improved pricing. However, shipment volume in the smokeable unit continued to decline.
Altria (MO) Tops Q4 Earnings Estimates
by Zacks Equity Research
Altria (MO) delivered earnings and revenue surprises of 1.06% and -0.42%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Altria (MO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Altria (MO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Altria's (MO) Q4 Earnings to Gain From Prudent Pricing & RRPs
by Zacks Equity Research
Altria (MO) gains from higher pricing as well as rising popularity of low risk tobacco products. However, declining cigarette sales volumes is a worry.
Why Marijuana ETF is on a High in 2019
by Sweta Killa
After being beaten down in the final quarter of 2018, pot stocks staged a nice comeback this year on the renewed appeal for riskier assets.
Altria (MO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $48.24 in the latest trading session, marking a -1.35% move from the prior day.
Zacks Market Edge Highlights: Tilray, Constellation Brands, Altria and GW Pharmaceuticals
by Zacks Equity Research
Zacks Market Edge Highlights: Tilray, Constellation Brands, Altria and GW Pharmaceuticals
Can Altria's Expansion in RRPs & Cannabis Enable a Revival?
by Zacks Equity Research
Altria (MO) strives to expand in RRPs and Cannabis to stay afloat, amid receding cigarette sales.